002294 信立泰
已收盘 05-06 15:00:00
资讯
新帖
简况
国金证券：给予信立泰买入评级
证券之星 · 04-23
国金证券：给予信立泰买入评级
信立泰(002294)3月31日股东户数2.54万户，较上期减少3.96%
证券之星 · 04-21
信立泰(002294)3月31日股东户数2.54万户，较上期减少3.96%
信立泰(002294.SZ)发布一季度业绩，归母净利润2.25亿元，同比增长12.45%
智通财经 · 04-20
信立泰(002294.SZ)发布一季度业绩，归母净利润2.25亿元，同比增长12.45%
信立泰（002294）披露JK06境外临床试验进展公告，4月20日股价下跌4.34%
证券之星 · 04-20
信立泰（002294）披露JK06境外临床试验进展公告，4月20日股价下跌4.34%
信立泰最新公告：JK06境外临床试验展现良好安全性和疗效
证券之星 · 04-19
信立泰最新公告：JK06境外临床试验展现良好安全性和疗效
4月16日信立泰（002294）龙虎榜数据：机构净卖出1398.89万元，北向资金净买入1780.85万元
证券之星 · 04-16
4月16日信立泰（002294）龙虎榜数据：机构净卖出1398.89万元，北向资金净买入1780.85万元
4月16日信立泰跌10.00%，浙商汇金转型成长基金重仓该股
证券之星 · 04-16
4月16日信立泰跌10.00%，浙商汇金转型成长基金重仓该股
信立泰跌10.00%，东吴证券二周前给出“买入”评级，目标价85.48元
证券之星 · 04-16
信立泰跌10.00%，东吴证券二周前给出“买入”评级，目标价85.48元
4月15日信立泰涨8.15%，浙商汇金转型成长基金重仓该股
证券之星 · 04-15
4月15日信立泰涨8.15%，浙商汇金转型成长基金重仓该股
新股消息 | 信立泰(002294.SZ)拟港股IPO 证监会要求说明募集资金境内外用途占比
智通财经网 · 04-03
新股消息 | 信立泰(002294.SZ)拟港股IPO 证监会要求说明募集资金境内外用途占比
信立泰（002294）披露SAL0132 I期临床关键数据，4月3日股价下跌2.78%
证券之星 · 04-03
信立泰（002294）披露SAL0132 I期临床关键数据，4月3日股价下跌2.78%
异动快报：信立泰（002294）3月27日13点30分触及涨停板
证券之星 · 03-27
异动快报：信立泰（002294）3月27日13点30分触及涨停板
信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验
智通财经 · 03-24
信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验
信立泰公布国际专利申请：“用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途”
证券之星 · 03-21
信立泰公布国际专利申请：“用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途”
信立泰最新公告：获得STC007在中国市场瘙痒适应症独家许可权益
证券之星 · 03-20
信立泰最新公告：获得STC007在中国市场瘙痒适应症独家许可权益
3月17日信立泰涨5.84%，中欧医疗健康混合A基金重仓该股
中金财经 · 03-17
3月17日信立泰涨5.84%，中欧医疗健康混合A基金重仓该股
信立泰（002294）披露变更部分募集资金用途用于高血压创新药临床研究公告，3月16日股价上涨5.65%
证券之星 · 03-16
信立泰（002294）披露变更部分募集资金用途用于高血压创新药临床研究公告，3月16日股价上涨5.65%
国金证券：首次覆盖信立泰给予买入评级，目标价70.36元
证券之星 · 03-12
国金证券：首次覆盖信立泰给予买入评级，目标价70.36元
创新药概念震荡反弹 信立泰涨停
每日经济新闻 · 03-10
创新药概念震荡反弹 信立泰涨停
异动快报：信立泰（002294）3月10日11点14分触及涨停板
证券之星 · 03-10
异动快报：信立泰（002294）3月10日11点14分触及涨停板
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物、医疗器械、骨科药物、头孢类抗生素、原料。截至报告期末，累计获得有效专利授权392项，其中境外授权（含港澳台地区）83项；正在申请566项，其中境外申请266项，PCT国际申请46项。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":50.64,"timestamp":1778051016000,"preClose":51.29,"halted":0,"volume":13567146,"delay":0,"changeRate":-0.0127,"floatShares":1115000000,"shares":1115000000,"eps":0.6068,"marketStatus":"已收盘","change":-0.65,"latestTime":"05-06 15:00:00","open":51,"high":52.02,"low":50.5,"amount":693000000,"amplitude":0.0296,"askPrice":50.65,"askSize":1,"bidPrice":50.64,"bidSize":49,"shortable":0,"etf":0,"ttmEps":0.6068,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778117400000},"marketStatusCode":5,"adr":0,"adjPreClose":51.29,"symbolType":"stock","openAndCloseTimeList":[[1778031000000,1778038200000],[1778043600000,1778050800000]],"highLimit":56.42,"lowLimit":46.16,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":6.25,"roa":"--","peRate":83.454186,"roe":"2.49%","epsLYR":0.58,"committee":0.891473,"marketValue":56454000000,"turnoverRate":0.0122,"status":1,"floatMarketCap":56442000000},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2629000717","title":"国金证券：给予信立泰买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2629000717","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629000717?lang=zh_cn&edition=full","pubTime":"2026-04-23 15:05","pubTimestamp":1776927928,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,唐玉青近期对信立泰进行研究并发布了研究报告《创新转型加速验证，JK07数据读出在即》，给予信立泰买入评级。此外，信超妥的HFrEF适应症正在开展III期临床，计划于26年内完成并递交上市NDA。 风险提示 创新药放量不及预期风险、线上渠道竞争加剧风险最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为74.18。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300037281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629791081","title":"信立泰(002294)3月31日股东户数2.54万户，较上期减少3.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629791081","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629791081?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:16","pubTimestamp":1776763002,"startTime":"0","endTime":"0","summary":"证券之星消息，近日信立泰披露，截至2026年3月31日公司股东户数为2.54万户，较12月31日减少1046.0户，减幅为3.96%。在化学制药行业个股中，信立泰股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.53万户。从股价来看，2025年12月31日至2026年3月31日，信立泰区间涨幅为23.73%，在此期间股东户数减少1046.0户，减幅为3.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100038933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","BK0188","BK0239","BK0187","002294","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628372327","title":"信立泰(002294.SZ)发布一季度业绩，归母净利润2.25亿元，同比增长12.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628372327","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628372327?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:56","pubTimestamp":1776689774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布2026年第一季度报告，第一季度，公司实现营业收入12.28亿元，同比增长15.65%。归属于上市公司股东的净利润2.25亿元，同比增长12.45%。归属于上市公司股东的扣除非经常性损益的净利润2.21亿元，同比增长15.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)发布一季度业绩，归母净利润2.25亿元，同比增长12.45%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628274519","title":"信立泰（002294）披露JK06境外临床试验进展公告，4月20日股价下跌4.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628274519","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628274519?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:13","pubTimestamp":1776676394,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘，信立泰报收于56.2元，较前一交易日下跌4.34%，最新总市值为626.53亿元。公司于近日披露《关于JK06境外临床试验进展的公告》。公告显示，深圳信立泰药业股份有限公司子公司美国Salubris Bio在AACR 2026年年会上公布了JK06的1/2期扩展队列临床数据。数据显示，JK06在非小细胞肺癌和乳腺癌患者中表现出良好的安全性和疗效。安全性方面，JK06总体耐受性良好，大部分不良事件为1级或2级，未出现4级或5级事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0196","BK0183","BK0028","BK0239","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628766065","title":"信立泰最新公告：JK06境外临床试验展现良好安全性和疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2628766065","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628766065?lang=zh_cn&edition=full","pubTime":"2026-04-19 16:30","pubTimestamp":1776587445,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司收到子公司SalubrisBio通知，其在美国癌症研究协会2026年年会上公布了JK06的1/2期扩展队列数据。数据显示，JK06在包括非小细胞肺癌和乳腺癌在内的不可切除局部晚期或转移性肿瘤患者中，展现出良好的安全性和疗效。其中，38例可评估的非小细胞肺癌患者客观缓解率为26%，19例可评估的乳腺癌患者ORR为26%。安全性方面，总体耐受性良好，未观察到4级或5级不良事件。目前JK06正在欧洲推进剂量拓展阶段研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900006308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0196","BK0188","BK0183","BK0239","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627295938","title":"4月16日信立泰（002294）龙虎榜数据：机构净卖出1398.89万元，北向资金净买入1780.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627295938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627295938?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:15","pubTimestamp":1776330941,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月16日公布的交易公开信息显示，信立泰因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月16日收盘，信立泰报收于60.54元，下跌10.0%，跌停，换手率2.11%，成交量23.54万手，成交额14.52亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出1398.89万元，北向资金合计净买入1780.85万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600031024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0187","BK0028","BK0183","BK0188","002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627298353","title":"4月16日信立泰跌10.00%，浙商汇金转型成长基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627298353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627298353?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:18","pubTimestamp":1776327484,"startTime":"0","endTime":"0","summary":"证券之星消息，4月16日信立泰跌10.00%，收盘报60.54元，换手率2.11%，成交量23.54万手，成交额14.52亿元。重仓信立泰的前十大公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为77.01。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为浙商证券资管的浙商汇金转型成长。该公募基金现任基金经理为马斌博。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600028309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","BK0188","BK0196","BK0187","BK0239","002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627988312","title":"信立泰跌10.00%，东吴证券二周前给出“买入”评级，目标价85.48元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627988312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627988312?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:17","pubTimestamp":1776327474,"startTime":"0","endTime":"0","summary":"今日信立泰跌10.00%，收盘报60.54元。2026年4月1日，东吴证券研究员朱国广发布了对信立泰的研报《慢病领域创新龙头，心衰重磅JK07潜力大》，该研报对信立泰给出“买入”评级，认为其目标价为85.48元，研报发布时股价为61.31元，预期涨幅为39.42%。基于DCF模型估值计算合理企业市值为919.03亿元，对应合理目标价为85.48元。公司国内商业化推进顺利，重磅单品潜力大，在研品种丰富全面，首次覆盖给予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600028304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627840476","title":"4月15日信立泰涨8.15%，浙商汇金转型成长基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627840476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627840476?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:11","pubTimestamp":1776240672,"startTime":"0","endTime":"0","summary":"证券之星消息，4月15日信立泰涨8.15%，收盘报67.27元，换手率1.84%，成交量20.52万手，成交额13.08亿元。重仓信立泰的前十大公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为77.01。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为浙商证券资管的浙商汇金转型成长。该公募基金现任基金经理为马斌博。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500028569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","BK0187","BK0196","002294","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624654971","title":"新股消息 | 信立泰(002294.SZ)拟港股IPO 证监会要求说明募集资金境内外用途占比","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654971","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624654971?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:53","pubTimestamp":1775213634,"startTime":"0","endTime":"0","summary":"证监会要求信立泰补充说明募集资金境内外用途占比，是否计划调回境内及调回境内的具体比例，是否涉及投向境外投资项目，是否已履行必要的主管部门审批、核准、备案等程序。同时，证监会要求信立泰按照《监管规则适用指引——境外发行上市类第2号》要求，说明有限责任公司时期设立及股本股东变化情况。截至最后实际可行日期，根据弗若斯特沙利文的资料，该公司拥有按规模计国内企业中第二大的心肾代谢综合征创新药管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["SPCK","BK0188","002294","BK4588","BK4585","VXUS","BK0196","BK0187","SPCX","BK0183","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624045656","title":"信立泰（002294）披露SAL0132 I期临床关键数据，4月3日股价下跌2.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624045656","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624045656?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:22","pubTimestamp":1775208176,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，信立泰报收于66.4元，较前一交易日下跌2.78%，最新总市值为740.24亿元。该股当日开盘66.96元，最高68.05元，最低66.0元，成交额达6.9亿元，换手率为0.93%。近日，深圳信立泰药业股份有限公司披露关于SAL0132研发进展的公告。公告显示，其与成都国为合作开发的siRNA创新药SAL0132在2026年美国心脏病学会科学年会上发布了I期临床研究关键数据。SAL0132为靶向肝脏AGT的GalNAc偶联siRNA药物，目前正开展II期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","002294","BK0188","BK0239","BK0183","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622557817","title":"异动快报：信立泰（002294）3月27日13点30分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2622557817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622557817?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:35","pubTimestamp":1774589728,"startTime":"0","endTime":"0","summary":"证券之星3月27日盘中消息，13点30分信立泰触及涨停板。其所属行业化学制药目前上涨。领涨股为舒泰神。该股为减肥药，创新药，基因编辑概念热股，当日减肥药概念上涨4.75%，创新药概念上涨4.52%，基因编辑概念上涨4.36%。3月26日的资金流向数据方面，主力资金净流出2514.12万元，占总成交额7.99%，游资资金净流入163.03万元，占总成交额0.52%，散户资金净流入2351.09万元，占总成交额7.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700024712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0183","002294","BK0187","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621057186","title":"信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621057186","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621057186?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:45","pubTimestamp":1774341908,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新药物SAL0145注射液(项目代码：SAL0145)开展MASH适应症的临床试验。SAL0145是公司研发的具有自主知识产权的siRNA药物。临床前研究显示，其具有治疗MASH的潜力。若能研发成功并获批上市，将有望为更多患者提供新的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159992","BK0187","002294","BK0196","06978","BK0188","BK0239","BK0183","BK1161","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621752220","title":"信立泰公布国际专利申请：“用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621752220?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:54","pubTimestamp":1774043674,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示信立泰（002294）公布了一项国际专利申请，专利名为“用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途”，专利申请号为PCT/CN2025/120921，国际公布日为2026年3月19日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来信立泰已公布的国际专利申请6个，与去年同期持平。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.35亿元，同比增16.31%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032100004161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002294","BK0028","BK0239","BK0183","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620733562","title":"信立泰最新公告：获得STC007在中国市场瘙痒适应症独家许可权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2620733562","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620733562?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:51","pubTimestamp":1774007481,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司与成都诺和晟泰生物科技有限公司签署协议，获得STC007原料药及制剂在中国市场所有瘙痒适应症的独家许可权益，涵盖研发、注册、生产及商业化等。首付款及研发里程碑款合计最高不超过1.25亿元，销售里程碑款累计最高不超过7.25亿元，总金额合计不超过8.5亿元。STC007为外周κ阿片受体激动剂，目前正开展慢性肾脏病相关中至重度瘙痒适应症II期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000037389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002294","BK0188","BK0239","BK0028","BK0183","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620442542","title":"3月17日信立泰涨5.84%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442542","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620442542?lang=zh_cn&edition=full","pubTime":"2026-03-17 16:25","pubTimestamp":1773735915,"startTime":"0","endTime":"0","summary":"证券之星消息，3月17日信立泰涨5.84%创60日新高，收盘报58.58元，换手率1.53%，成交量17.04万手，成交额9.8亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共51家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.7241，较上一交易日上涨0.67%，近一年上涨7.71%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/17/20260317439899.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/17/20260317439899.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260317/32074670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","BK0196","BK4588","159760","BK0188","XBI","BK0028","BK4585","BK0187","XLV","LABU","002294","BK4581","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619245504","title":"信立泰（002294）披露变更部分募集资金用途用于高血压创新药临床研究公告，3月16日股价上涨5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619245504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619245504?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:12","pubTimestamp":1773652338,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，信立泰报收于55.35元，较前一交易日上涨5.65%，最新总市值为617.05亿元。近日，深圳信立泰药业股份有限公司发布《关于签订募集资金三方监管协议的公告》。公告显示，公司因变更部分募集资金用途，将原项目“S086沙库巴曲阿利沙坦钙中国II/III期临床研究及上市注册项目”中的30,100万元募集资金用于新项目“部分高血压创新药II/III期临床研究及上市注册项目”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600023232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0028","BK1574","BK0196","BK0188","BK0239","159992","06978","BK1161","BK0187","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618195180","title":"国金证券：首次覆盖信立泰给予买入评级，目标价70.36元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618195180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618195180?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:34","pubTimestamp":1773308044,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,唐玉青近期对信立泰进行研究并发布了研究报告《深耕心肾代谢综合征，心衰新药JK07潜力巨大》，首次覆盖信立泰给予买入评级，目标价70.36元。2月13日，公司已正式提交H股上市申请。基于DCF估值模型，计算合理市值为784亿元，对应合理目标价为70.36元。首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200030941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618003836","title":"创新药概念震荡反弹 信立泰涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2618003836","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618003836?lang=zh_cn&edition=full","pubTime":"2026-03-10 11:16","pubTimestamp":1773112560,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月10日，创新药概念盘中震荡反弹，信立泰涨停，海特生物、维康药业（维权）涨超10%，苑东生物、百利天恒、荣昌生物、海思科、科伦药业涨幅靠前。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-10/doc-inhqnmhs6364450.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-10/doc-inhqnmhs6364450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK1574","159992","BK0196","BK1161","BK0188","BK0183","BK0028","BK0187","002294","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618074536","title":"异动快报：信立泰（002294）3月10日11点14分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2618074536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618074536?lang=zh_cn&edition=full","pubTime":"2026-03-10 11:15","pubTimestamp":1773112521,"startTime":"0","endTime":"0","summary":"证券之星3月10日盘中消息，11点14分信立泰触及涨停板。其所属行业化学制药目前上涨。领涨股为信立泰。该股为基因编辑，创新药，医疗器械概念热股，当日基因编辑概念上涨1.82%，创新药概念上涨1.82%，医疗器械概念上涨1.63%。3月9日的资金流向数据方面，主力资金净流入2753.88万元，占总成交额7.64%，游资资金净流入907.21万元，占总成交额2.52%，散户资金净流出3661.09万元，占总成交额10.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000013538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0196","BK0183","002294","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778060108872,"stockEarnings":[{"period":"1week","weight":-0.0836},{"period":"1month","weight":-0.1634},{"period":"3month","weight":0.0934},{"period":"6month","weight":-0.1396},{"period":"1year","weight":0.2703},{"period":"ytd","weight":0.0351}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25382人(较上一季度减少3.96%)","perCapita":"43911股","listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","registeredCapital":"111481万元","survey":" 深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物、医疗器械、骨科药物、头孢类抗生素、原料。截至报告期末，累计获得有效专利授权392项，其中境外授权（含港澳台地区）83项；正在申请566项，其中境外申请266项，PCT国际申请46项。","listedPrice":41.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}